AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 121 min read$QNRX

BTIG initiates coverage of Quoin Pharmaceuticals with Buy rating, $14 price target

BTIG initiated coverage of Quoin Pharmaceuticals with a Buy rating and $14 price target, implying a 211.1% upside from the Oct 9 close of $4.50. The firm cited strong clinical data for QRX003 in treating Netherton Syndrome and a significant market opportunity exceeding $3 billion.

Original reporting
tradingview.com
Published Oct 12, 2026, 10:19 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 10:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
BTIG initiates coverage of Quoin Pharmaceuticals with Buy rating, $14 price target — source image
Source · tradingview.com
Decision brief

The 30-second read

$QNRXBullishMed
01

Why it matters

The note could attract new capital and increase volatility.

02

Market read

First analyst rating for QNRX, likely to influence short‑term price action.

03

What to watch

Potential regulatory delays or competition could temper upside.

Relevance 7/10Novelty 7/10Timing: today

Background

BTIG’s new coverage adds a fresh analyst perspective on Quoin Pharmaceuticals.

Company-level read

Ticker impact

$QNRXBullishHigh confidence
Context

BTIG initiated coverage with a Buy rating and a $14 price target, implying a 211% upside from the recent close.

Expected impact

upward pressure as investors price in the new target

Evidence & confidence

The coverage is the first BTIG note on QNRX and sets a substantially higher valuation than current market price.

Market effects

Sector

Positive signal may lift sentiment in the rare‑disease biotech sector.

Regional

Limited to U.S. biotech investors.

Global

Minimal beyond niche biotech community.

Counterpoint

What could challenge this read

The clinical data are early‑stage; the target may be overly optimistic.

Key entities

  • company
    Quoin Pharmaceuticals

    Biotech firm developing QRX003 for Netherton Syndrome.

  • analyst_firm
    BTIG

    Investment bank providing the coverage and price target.

Read at source← All news

Related articles

OCT 20
$QNRXMedAI 8/10

Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy

Quoin Pharmaceuticals Ltd. (QNRX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy – Peer-Reviewed Paper Introducing QRX003 and Its Mechanism of Action in Netherton Syndrome Now Published – Case Report Details 21 Months of

SEC EDGAR 8-K2 min
OCT 19
$QNRXMedAI 8/10

Canaccord initiates Quoin Pharmaceuticals stock at buy on rare skin disease drug potential

Canaccord Genuity initiated coverage on Quoin Pharmaceuticals (QNRX) with a buy rating and $18 price target, citing its lead drug QRX003 for Netherton syndrome. The stock is down 74% over a year. Phase 2/3 study met primary endpoint, with topline data expected in 2027. Canaccord projects 2028 launch and $300M peak sales. BTIG also initiated coverage with a buy rating and $14 target.

investing.com1 min
OCT 14
$QNRXMedAI 8/10

Quoin Secures EMA Orphan Drug Designation For QRX003 In Rare Skin Disorder

Quoin Pharmaceuticals (QNRX) received EMA Orphan Drug Designation for QRX003 to treat Peeling Skin Syndrome, a rare skin disorder. The designation offers development incentives and potential market exclusivity. QNRX plans to start clinical trials for PSS by year-end. QRX003 has also received U.S. and Japanese designations for rare diseases. QNRX stock closed at $4.15, down 4.82%.

rttnews.com2 min
OCT 14
$QNRXMedAI 8/10

Quoin Pharmaceuticals Gains EMA Orphan Status for QRX003

Quoin Pharmaceuticals (QNRX) announced that the European Medicines Agency granted Orphan Drug Designation to its lead candidate QRX003 for Peeling Skin Syndrome. This status offers incentives and potential market exclusivity. The company is on track to launch a clinical study by year-end. Analysts have a $14.00 price target, but Spark's AI rates it Neutral due to financial performance and technicals.

tipranks.com2 min